DECRYPTION – Accessible in France for a year, the treatment radically changes the quality of life of patients.
Some mentioned “a therapeutic revolution” for patients with cystic fibrosis. A year after the establishment of its reimbursement, the Kaftrio has largely fulfilled its promise. The 2021 report from the French Cystic Fibrosis Registry, the results of which were published on Thursday, September 15, highlights the impressive real-life beneficial effects of this innovative treatment which targets the most common rare disease in Europe, a genetic pathology that makes secrete excess mucus and greatly reduces life expectancy. “The evolution is positive on all clinical indicators, and this trend seems to be confirmed in 2022 with the increase in the number of prescriptions”, rejoices Paola de Carli, director of the research department of Vaincre la mucoviscidose. The patient association maintains and updates the epidemiological monitoring of more than 7,500 people (ie almost all French patients).
Produced by the American laboratory Vertex Pharmaceuticals…
This article is for subscribers only. You have 80% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
Already subscribed? Login